A Study of SL-325 in Participants With Hidradenitis Suppurativa
Key facts
- Phase
- Phase 2
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shattuck Labs, Inc.
- Trial code
- NCT07934017
- Record updated
- 12 November 2026
- Original description
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa.Read full original descriptionShow less
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderate to Severe Hidradenitis Suppurativa (RECEPTIVE-HS1)
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa.
The study consists of a screening period of up to 5 weeks, a 16-week primary treatment period, 36-week extension period, and a follow-up period of up to 12 weeks.
Inclusion: A clinical diagnosis of HS at Screening as assessed by the Investigator; Signs and symptoms of HS for ≥6 months prior to Screening; ≥5 total AN count; HS lesions present in ≥2 distinct anatomical areas; ≥1 anatomic area of HS involvement characterized as Hurley Stage II or III; Draining tunnel count of ≤20; Inadequate response or recurrence of disease activity after an appropriate course of systemic antibiotics for the treatment of HS OR intolerance or contraindication to systemic antibiotics for the treatment of HS.
Exclusion: Prior exposure to any anti-DR3 or anti-TL1A agent or agent with an anti-DR3 or anti-TL1A component; Evidence of other active skin disease or condition that could, in the Investigator's opinion, interfere with the evaluation of HS; Active tuberculosis (TB) or inadequately treated latent tuberculosis infection (LTBI).